Abstracts tagged "interstitial lung disease"

Abstract Number: 2008 • 2017 ACR/ARHP Annual Meeting
“Intrathoracic Manifestations of Connective Tissue Diseases on High Resolution Computed Tomography”
Diego Baenas¹, Maira Orozco², María Eugenia Olmos³, Luis Lasca⁴, Paula Riba⁵, Patricio Muszinsky⁵, Juan Pablo Pirola⁶, Verónica Saurit⁷, Alejandro Alvarellos⁷, Ana C. Alvarez⁸, Soledad Retamozo^9,10, Nadia Riscanevo^7,11, Janet Flores¹², Ariel Blua³, Ana María López¹³, Gustavo Muiño¹⁴, Santiago Orozco¹⁵ and Francisco Caeiro¹⁶, ¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Postgraduate Career of Rheumatology Catholic University of Córdoba., Cordoba, Argentina, ²Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³Pulmonary, Pulmonary Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁴Radiology Unit, Oulton Institute, Cordoba, Argentina, ⁵Radiology, Radiology Unit, Oulton Institute, Cordoba, Argentina, ⁶Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ⁷Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁸Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ¹⁰Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ¹¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹²Rheumatology Unit, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹³Pulmonary Unit, Pulmonary Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁴Radiology, Radiology Unit,Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁵Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁶Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina
Background/Purpose: Connective tissue diseases (CTD) can cause intrathoracic involvement, increasing patients morbidity and mortality. High-resolution computed tomography (HRCT) is a key method for evaluation of…
Abstract Number: 843 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension: Data from the Pharos Registry
Joyce Sujin Lee¹, Jessica K. Gordon², Jackie Szymonifka³, Virginia Steen⁴ and Aryeh Fischer⁵, ¹SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Georgetown University School of Medicine, Washington, DC, ⁵Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO
Forced vital capacity predicts outcome in scleroderma associated interstitial lung disease with concomitant pulmonary hypertension: Data from the PHAROS registry Background/Purpose: Interstitial lung disease…
Abstract Number: 2891 • 2016 ACR/ARHP Annual Meeting
Prognostic Significance of Autoantibody Positivity in Interstitial Lung Disease: A Retrospective Case-Control Study
Christos F Kampolis¹, Aliki I Venetsanopoulou¹, Fotini Karakontaki², Vlassis Polychronopoulos², Panayiotis G Vlachoyiannopoulos¹ and Athanasios G. Tzioufas³, ¹Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Respiratory Medicine, “Hygeia” Hospital, Athens, Greece, ³School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Routine screening for circulating autoantibodies (AAbs) on the initial evaluation of interstitial lung disease (ILD) contributes to the diagnosis of underlying autoimmune disease. However,…
Abstract Number: 845 • 2016 ACR/ARHP Annual Meeting
Current Use of Off-Label Therapies in Systemic Sclerosis-Associated Interstitial Lung Disease
Elise Siegert¹, Dörte Huscher², Ulf Müller-Ladner³, Veronika K. Jaeger⁴, Ulrich A. Walker⁴, Marc Frerix⁵, László Czirják⁶, Francesco Del Galdo⁷, Gabriele Valentini⁸, Marco Matucci-Cerinic⁹, Yannick Allanore¹⁰, Oliver Distler¹¹, Christopher Denton¹², Gabriela Riemekasten¹³ and EUSTAR co-authors, ¹Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁴Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁵Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁶Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ⁷Musculoskeletal Diseases, Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, ⁸Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁹Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ¹⁰Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ¹¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹³Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a connective tissue disease that is often complicated by secondary interstitial lung disease (SSc-ILD). Due to its high morbidity and…
Abstract Number: 2892 • 2016 ACR/ARHP Annual Meeting
Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low
Tamao Nakashita¹, Shinji Motojima², Akira Jibatake², Akira Yoshida² and Yoshiki Yamamoto², ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: KL-6 is a glycoprotein expressed on and released from type 2 alveolar cells and the measurement of KL-6 in serum was developed by Kohno…
Abstract Number: 847 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis
Anna Hoffmann-Vold¹, Elizabeth R. Volkmann², Oyvind Midtvedt³, Torhild Garen³, Anders Heiervang Tennøe³, Trond Mogens Aalokken⁴, May Brit Lund⁵ and Øyvind Molberg³, ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Respiratory Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but there are no valid methods for early detection of SSc-ILD or…
Abstract Number: 2904 • 2016 ACR/ARHP Annual Meeting
Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients
Gul Guzelant¹, Melike Melikoglu¹, Benan Musellim², Deniz Demir Yilmaz², Izzet Fresko¹, Emire Seyahi¹, Gulen Hatemi¹, Serdal Ugurlu¹ and Vedat Hamuryudan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Pulmonary Medicine, Istanbul, Turkey
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of systemic sclerosis (SSc). Immunosuppressives such as cyclophosphamide (CYC) and mycophenolate mophetil (MMF) are used in…
Abstract Number: 852 • 2016 ACR/ARHP Annual Meeting
Targeting Fibroblastoid-like Cells By Drug Loaded Engineered Gold Nanoparticles As a Novel Approach for ILD-SSc Treatment
Veronica Codullo¹, Emanuela Cova², Simona Inghilleri², Miriam Colombo³, Davide Prosperi³, Federica Meloni⁴ and Carlomaurizio Montecucco⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ²Clinica di Malattie dell’Apparato Respiratorio, IRCCS Fondazione Policlinico S Matteo, Pavia, Italy, Pavia, Italy, ³Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milan, Italy, ⁴Dipartimento di Medicina Interna, Unità di Pneumologia e UOC di Reumatologia, Università di Pavia, Pavia, Italy, ⁵Rheumatology Unit of the University Hospital of Pavia, Pavia, Italy
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune fibrotic disorder characterised by collagen and extracellular matrix deposition in the skin and internal organs, such as the…
Abstract Number: 2912 • 2016 ACR/ARHP Annual Meeting
Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)
Caitlyn Fisher^1,2, Rajaie Namas³, Amber Young², Holly Wilhalme⁴ and Dinesh Khanna⁵, ¹Cognitive Science / Creative Writing, Beloit College, Beloit, WI, ²Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: PROMIS-29 is a generic health-related quality of life (HRQoL) instrument that was developed as part of the NIH Patient Reported Outcomes (PROs) Roadmap. Our…
Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Suzanne Kafaja¹, Philip J. Clements², Holly Wilhalme³, Daniel E. Furst⁴, Chi-hong Tseng², Kim Hyun⁵, Jonathan Goldin³, Elizabeth R. Volkmann³, Michael Roth², Donald P. Tashkin⁶ and Dinesh Khanna⁷, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…
Abstract Number: 3249 • 2016 ACR/ARHP Annual Meeting
Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Dinesh Khanna², Chi-hong Tseng³, Robert Elashoff⁴, Bingling Wang⁵, Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Arthur Theodore⁶ and Donald P. Tashkin⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁵Biostatistics, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine, Boston University, Boston, MA, ⁷David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: While chronic cough occurs in the majority of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD),1 its impact on quality of life has not…
Abstract Number: 1236 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs
Karina Raimundo¹, Amanda Farr², Ashley Cole³ and Jeffrey J. Swigris⁴, ¹Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Truven Health Analytics, Bethesda, MD, ⁴Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO
Background/Purpose: Interstitial lung disease (ILD) is commonly associated with rheumatoid arthritis (RA) and can have significant morbidity and mortality. The objective was to calculate the…
Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting
Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Megan Forney¹, Richard Bell², Edward Schwarz³ and Homaira Rahimi⁴, ¹Orthopedics, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…
Abstract Number: 1501 • 2016 ACR/ARHP Annual Meeting
The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Katherine Larson¹, Faizah Siddique² and Samya Mohammad¹, ¹Virginia Commonwealth University, Richmond, VA, ²Department of Veterans Affairs, Richmond, VA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic disease with a known association with lymphoma and interstitial lung disease (ILD). ILD is a frequent extraarticular manifestation…
Abstract Number: 1559 • 2016 ACR/ARHP Annual Meeting
Shared Genetic Predisposition in Rheumatoid Arthritis–Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: A Genetic Association Study
Pierre-Antoine Juge¹, Raphaël Borie², Caroline Kannengiesser³, Steven Gazal³, Patrick Revy⁴, Lidwine Wemeau-Stervinou⁵, Marie-Pierre Debray⁶, Sébastien Ottaviani⁷, Sylvain Adam-Marchand⁸, Nadia Nathan⁹, Gabriel Thabut¹⁰, Christophe Richez¹¹, Hilario Nunes¹², Isabelle Callebaut¹³, Aurélien Justet², Nicolas Leulliot¹⁴, Amélie Bonnefond¹⁵, David Salgado¹⁶, Pascal Richette¹⁷, Jean-Pierre Desvignes¹⁶, Huguette Lioté¹⁸, Philippe Froguel¹⁵, Yannick Allanore¹⁹, Olivier Sand¹⁵, Claire Dromer²⁰, René-Marc Flipo²¹, Annick Clément⁹, Christophe Béroud²², Jean Sibilia²³, Baptiste Coustet^1,24, Vincent Cottin²⁵, Marie-Christophe Boissier²⁶, Benoit Wallaert²⁷, Thierry Schaeverbeke²⁸, Florence Dasto le Moal²⁹, Aline Frazier¹⁷, Christelle Ménard³⁰, Martin Soubrier³¹, Nathalie Saidenberg²⁹, Dominique Valeyre³², Serge Amselem⁹, Catherine Boileau³, Bruno Crestani² and Philippe Dieudé¹, ¹Rhumatologie, Hôpital Bichat - Claude Bernard, Paris, France, ²Pneumologie A, Hôpital Bichat - Claude Bernard, Paris, France, ³Génétique, Hôpital Bichat - Claude Bernard, Paris, France, ⁴Laboratory of Genome Dynamics in the Immune System, Institut Imagine, Paris, France, ⁵Pneumologie, CHRU de Lille, Lille, France, ⁶Université Paris-Diderot, Paris, France, ⁷Rheumatologie, Hôpital Bichat - Claude Bernard, Paris, France, ⁸Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁹Pneumologie pédiatrique, Hôpital Trousseau, Paris, France, ¹⁰Pneumologie B, Hôpital Bichat - Claude Bernard, Paris, France, ¹¹Rhumatologie, Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ¹²Pneumologie B, Hôpital Avicenne, Paris, France, ¹³CNRS UMR_7590, Paris, France, ¹⁴Laboratoire de cristallographie et RMN biologiques, UMR CNRS 8015, Paris, France, ¹⁵CNRS UMR_8199, Lille, France, ¹⁶UMR_S 910, Marseille, France, ¹⁷Rhumatologie, Hôpital Lariboisière, Paris, France, ¹⁸Pneumologie A, Hôpital Tenon, Paris, France, ¹⁹Rhumatologie A, Hôpital Cochin, Paris, France, ²⁰Imagerie Thoracique et Cardiovasculaire, CHU Bordeaux, Bordeaux, France, ²¹Rhumatologie, CHU Lille, Lille, France, ²²INSERM UMR_S 910, Marseille, France, ²³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁴Rheumatology, Université Paris Descartes, Hopital Cochin, Paris, France, ²⁵Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, ²⁶Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²⁷Pneumology, CHRU, Lille CEDEX, France, ²⁸Rheumatology, CHU Bordeaux, Bordeaux, France, ²⁹Rhumatologie, Hôpital Avicenne, Paris, France, ³⁰Pneumologie Pédiatrique, Hôpital Trousseau, Paris, France, ³¹Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³²Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality for rheumatoid arthritis (RA) patients. Despite its high prevalence and mortality, little…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.